1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Tuberculosis Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Tuberculosis Diagnostics Market, by Test Type
8.1.1. Radiographic Method
8.1.1.1. Market Revenue and Forecast
8.1.2. Diagnostic Laboratory Methods
8.1.2.1. Market Revenue and Forecast
8.1.3. Nucleic Acid Testing
8.1.3.1. Market Revenue and Forecast
8.1.4. Phage Assay
8.1.4.1. Market Revenue and Forecast
8.1.5. Detection of Latent Infection (Skin Test & IGRA)
8.1.5.1. Market Revenue and Forecast
8.1.6. Cytokine Detection Assay
8.1.6.1. Market Revenue and Forecast
8.1.7. Detection of Drug Resistance (DST)
8.1.7.1. Market Revenue and Forecast
8.1.8. Other Methods
8.1.8.1. Market Revenue and Forecast
9.1. Tuberculosis Diagnostics Market, by End-use
9.1.1. Diagnostic Laboratories
9.1.1.1. Market Revenue and Forecast
9.1.2. Hospitals & Clinics
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type
10.1.2. Market Revenue and Forecast, by End-use
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type
10.1.3.2. Market Revenue and Forecast, by End-use
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type
10.1.4.2. Market Revenue and Forecast, by End-use
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type
10.2.2. Market Revenue and Forecast, by End-use
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type
10.2.3.2. Market Revenue and Forecast, by End-use
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type
10.2.4.2. Market Revenue and Forecast, by End-use
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type
10.2.5.2. Market Revenue and Forecast, by End-use
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type
10.2.6.2. Market Revenue and Forecast, by End-use
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type
10.3.2. Market Revenue and Forecast, by End-use
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type
10.3.3.2. Market Revenue and Forecast, by End-use
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type
10.3.4.2. Market Revenue and Forecast, by End-use
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type
10.3.5.2. Market Revenue and Forecast, by End-use
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type
10.3.6.2. Market Revenue and Forecast, by End-use
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type
10.4.2. Market Revenue and Forecast, by End-use
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type
10.4.3.2. Market Revenue and Forecast, by End-use
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type
10.4.4.2. Market Revenue and Forecast, by End-use
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type
10.4.5.2. Market Revenue and Forecast, by End-use
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type
10.4.6.2. Market Revenue and Forecast, by End-use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type
10.5.2. Market Revenue and Forecast, by End-use
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type
10.5.3.2. Market Revenue and Forecast, by End-use
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type
10.5.4.2. Market Revenue and Forecast, by End-use
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Becton, Dickinson and Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. F. Hoffmann-La Roche AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Thermo Fisher Scientific Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. BioMérieux SA
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hain Lifescience GmbH
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. QIAGEN GmbH
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cepheid
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Hologic, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BD
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
